Drugs / DCR-PDL1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06504368 | May 2024 → Jun 2026 overdue | — | Dicerna Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCR-PDL1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504368 ↗ |
| Route | Intravenous | “intravenous DCR-PDL1” NCT06504368 ↗ |